New drug ZULRESSO offers hope for moms with postpartum depression
NCT ID NCT03924492
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This program provides early access to ZULRESSO (brexanolone) for adult women with postpartum depression before the drug is widely available. Eligible women receive a one-time injection under medical supervision. The goal is to help ease severe depression symptoms quickly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brexanolone (ZULRESSO) injection
What this could lead to
If successful, this program could provide a new treatment option for women with postpartum depression, potentially easing severe symptoms quickly.
What could go wrong
This is an expanded access program, not a controlled trial, so results may not be generalizable. Risks include side effects like sedation or sudden loss of consciousness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.